Adverse Drug Reactions Reported by Healthcare Professionals: Reaction Characteristics and Time to Reporting
Overview
Authors
Affiliations
We describe adverse drug reaction (ADR) reporting characteristics and factors contributing to length of time to report by healthcare professionals. This is a retrospective study of voluntary reports to an Australian healthcare ADR Review Committee over a 2-year period (2015-2016). Descriptive and univariate models were used for outcomes, employing standardized ADR definitions. Hospital pharmacists reported 84.8% of the 555 ADRs: 70.3% were hospital onset reactions, and 71.7% were at least of moderate severity. Immunologically mediated reactions were most commonly reported (409, 73.7%). The median time to submit an ADR report was 3 (interquartile range 1-10) days. Longer median times to reporting were associated with multiple implicated agents and delayed hypersensitivity reactions, especially severe cutaneous adverse reactions. A total of 650 medications were implicated that involved multiple agents in 165/555 (29.7%) reports. Antimicrobials were the most commonly implicated agents. Immunologically mediated reactions were most commonly associated with antimicrobials and radiocontrast agents (P < .0001, odds ratio [OR] 3.6, 95%CI 2.4-5.5, and P = .04, OR 4.2, 95%CI 1.2-18.2, respectively). Opioids and psychoactive medications were more commonly implicated in nonimmunological reported ADRs (P = .0002, OR 3.9, 95%CI 1.9-7.9, and P < .0001, OR 11.4, 95%CI 4.6-27.8, respectively). Due to the predominant reporting of immunologically mediated reactions, a targeted education program is being planned to improve identification and accuracy of ADR reports, with the overall aim of improved management to ensure quality service provision and patient safety.
Buabeng R, Dsane-Aidoo P, Asamoah Y, Bandoh D, Boahen Y, Sabblah G PLoS One. 2023; 18(9):e0291482.
PMID: 37699058 PMC: 10497160. DOI: 10.1371/journal.pone.0291482.
Aung A, Zubrinich C, Goh M, Snyder B, Tang M, Khu C Eur J Clin Pharmacol. 2023; 79(4):513-522.
PMID: 36806970 PMC: 10038939. DOI: 10.1007/s00228-023-03457-9.
Reporting, Monitoring, and Handling of Adverse Drug Reactions in Australia: Scoping Review.
Tagne J, Yakob R, Dang T, Mcdonald R, Wickramasinghe N JMIR Public Health Surveill. 2023; 9:e40080.
PMID: 36645706 PMC: 9887513. DOI: 10.2196/40080.
Aung A, Walker S, Khu Y, Tang M, Lee J, Graudins L Eur J Clin Pharmacol. 2022; 78(5):781-791.
PMID: 35171316 PMC: 9005418. DOI: 10.1007/s00228-022-03287-1.
Lavallee M, da Silveira C, Akinola S, Methot J, Piche M, Berard A Drugs Real World Outcomes. 2021; 9(1):153-163.
PMID: 34529224 PMC: 8844319. DOI: 10.1007/s40801-021-00275-2.